Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Biogen: Clinical Trials & FDA Approval Profile

Biogen (Cambridge, MA) sponsors 61 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 22 active protocols (11 recruiting now), 19 completed protocols, and 12 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)32.8%
Median Closed Enrollment vs National (145 pts)155 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Biogen
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)61
Active Pipeline (Recruiting Now)22 (11)
Completed vs Stopped Early19 / 20 (32.8%)
Median Closed Actual Enrollment155 participants
Physical Hospital Site Disclosure84.6% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals12 (6 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Biogen
Hospital Research SiteLocationShared Protocols
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CA15
University of Colorado Anschutz Medical CampusAurora, CO14
Cleveland ClinicCleveland, OH13

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Biogen
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07219043A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular InflammatPhase IIRECRUITING
NCT06962800A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)Phase IIIRECRUITING
NCT06935357A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)Phase IIIRECRUITING
NCT04895241A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have SPhase IIIACTIVE NOT RECRUITING
NCT06685757A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated RejPhase IIIACTIVE NOT RECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Biogen across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Biogen Interactive Dossier, benchmark peers in Neurology, Psychiatry, and Pain, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI